30.92
price up icon0.10%   0.03
after-market Handel nachbörslich: 30.92
loading

Warum fällt Zai Lab Limited Adr-Aktie (ZLAB)?

Wir haben während der Handelssitzung 2024-10-08 einen Rückgang der Aktie Zai Lab Limited Adr (ZLAB) um 5.73% festgestellt. Obwohl dies auf normale Volatilität oder verschiedene interne und externe Faktoren zurückzuführen sein kann, beachten Sie bitte, dass wir die Situation aktiv beobachten und so schnell wie möglich zeitnahe Updates bereitstellen!
2023-08-28:

Zai Lab Health Care (ZLAB) went down 5.12% to $22.81 after presenting results from the phase 3 LUNAR trial evaluating TTFields therapy together with standard therapies for non-small cell lung cancer at the 2023 American Society of Clinical Oncology Annual Meeting.

https://twitter.com/AInvestOfficial/status/1696275441609322807

2023-06-07:

ZLAB's stock fell 14.55% after Zai Lab disclosed the phase 3 trial outcomes of its collaborative oncology therapy with NovoCure. Despite the favorable results, investors seemed unimpressed and expressed doubts about the study's methodology, suggesting that the comparison between TTFields and less effective therapy may have skewed the results.

https://www.fool.com/investing/2023/06/07/why-shares-of-zai-lab-are-dropping-wednesday/

2023-03-20:

In related news, after Director William Lis sold 5,434 shares of the business’s stock in a transaction, today Zai Lab Ltd. announced that its partner Karuna Therapeutics, Inc. (KRTX) reported its Phase 3 EMERGENT-3 trial met its primary endpoint for its lead investigational therapy KarXT in adults with schizophrenia. Karuna is planning to submit an NDA to the FDA in mid-2023. Despite the good news, there are still many concerns about the side effects of this investigational therapy and the risk of doing business in China.

$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):